参考文献/References:
[1] Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism[J]. J Atheroscler Thromb,2006,13(3):123-129.
[2] Kruit JK, Brunham LR, Verchere CB, et al. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus[J]. Curr Opin Lipidol,2010,2l(3):178-185.
[3] Yada T, Nakata M, Shiraishi T, et al. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells[J]. Br J Pharmacol,1999,126(5):1205-1213.
[4] Mascitelli L, Goldstein MR. Statins, cholesterol depletion and risk of incident diabetes[J]. Int J Cardiol, 2011,152(2):275-276.
[5] Xia F, Xie L, Mihic A, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells[J]. Endocrinology,2008,149(10):5136-5145.
[6] Sjöholm A, Berggren PO, Cooney RV. Gamma-tocopherol partially protects insulin-secreting cells against functional inhibition by nitric oxide[J]. Biochem Biophys Res Commun,2000,277(2):334-340.
[7] Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins[J]. J Biol Chem,2003,278(20):18368-18375.
[8] Rütti S, Ehses JA, Sibler RA, et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells[J]. Endocrinology,2009,150(10):4521-4530.
[9] Kruit JK, Kremer PH, Dai L, et al. Cholesterol efflux via ATP-binding cassette transporter A1(ABCAl)and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice[J]. Diabetologia,2010,53(6):1110-1119.
[10] Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis[J]. Science,2010,328(5985):1570-1573.
[11] Wijesekara N, Zhang LH, Kang MH, et al. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets[J]. Diabetes,2012,61(3):653-658.
[12] Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment[J]. Nat Med,2007,13(3):340-347.
[13] Kruit JK, Wijesekara N, Fox JE,et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules[J]. Diabetes,2011,60(12):3186-3196.
[14] Allen RM, Marquart TJ, Albert CJ, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity[J]. EMBO Mol Med,2012,4(9):882-895.
[15] Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins[J]. Atherosclerosis, 2011,215(1):1-8.
[16] Takagi T, Matsuda M, Abe M, et al.Effect of pravastatin on the development of diabetes and adiponectin production[J]. Atherosclerosis,2008,196(1):114-121.
[17] Koh KK, Quon MJ, Sakuma I, et al.Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients[J]. Int J Cardiol,2013,166(2):509-515.
[18] Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin[J]. Atheroscler Suppl,2015,16:1-27.
[19] Doehner W, Gathercole D, Cicoira M, et al.Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition[J]. Int J Cardiol,2010,138(1):19-24.
[20] Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4(SLC2A4): implications in glycaemic control[J].Diabetologia,2006,49(8):1881-1892.
[21] Preiss D, Sattar N. Statins and the risk of new-onset diabetes:a review of recent evidence[J]. Curr Opin Lipidol,2011,22(6):460-466.
[22] Supale S, Li N, Brun T, et al. Mitochondrial dysfunction in pancreatic β cells[J]. Trends Endocrinol Metab,2012,23(9):477-487.
[23] Phielix E, Mensink M. Type 2 diabetes mellitus and skeletal muscle metabolic function[J]. Physiol Behav,2008,94(2):252-258.
[24] Wang CH,Wang CC, Huang HC, et al. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes[J]. FEBS J,2013,280(4):1039-1050.
[25] Sirvent P, Fabre O, Bordenave S, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins[J]. Toxicol Appl Pharmacol,2012,259(2):263-268.
[26] Schrauwen P, Saris WH, Hesselink MK. An alternative function for human uncoupling protein 3: protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix[J]. FASEB J,2001,15(13):2497-2502.
[27] Krssak M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a1H NMR spectroscopy study[J]. Diabetologia,1999,42(1):113-116.
[28] Moro C, Bajpeyi S, Smith SR. Determinants of intramyocellular triglyceride turnover: implications for insulin sensitivity[J]. Am J Physiol Endocrinol Metab,2008,294(2):e203-e213.
[29] Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance[J]. J Am Coll Cardiol,2013,61(1):44-53.